Treatment of medical induced psychosis in Parkinson disease;Die therapie medikamenteninduzierter psychotischer symptome beim morbus Parkinson

Aktuelle Neurologie

Volumn 31, Issue 7, 2004, Pages 361-365

  Witt, K ^a   Reiff, J ^a   Deuschl, G ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZODIAZEPINE DERIVATIVE; C REACTIVE PROTEIN; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOMETHIAZOLE; CLOZAPINE; CREATININE; DONEPEZIL; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; GLUCOSE; HALOPERIDOL; LEVODOPA; LEVOMEPROMAZINE; MELPERONE; MIDODRINE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN 3 ANTAGONIST; UNINDEXED DRUG; ZIPRASIDONE;

AGING; AGRANULOCYTOSIS; AUDITORY HALLUCINATION; BLOOD CELL COUNT; CLINICAL TRIAL; CONSENSUS; CONSTIPATION; DELIRIUM; DEMENTIA; DEPRESSION; DISEASE DURATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; INFECTION; LOW DRUG DOSE; METABOLIC DISORDER; MOTOR DYSFUNCTION; NERVE DEGENERATION; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PRACTICE GUIDELINE; PSYCHOSIS; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; SYNCOPE; VISUAL HALLUCINATION;

EID: 4644337957     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-815021     Document Type: Review

References (38)

1. Agid Y, Arnulf I, Bejjani P et al. Parkinson's disease is a neuropsychiatric disorder. Adv Neurol 2003; 91: 365-370
2. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595-601
3. Hantz P, Caradoc-Davies G, Caradoc-Davies T et al. Depression in Parkinson's disease. Am J Psychiatry 1994; 151: 1010-1014
4. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381-389
5. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745
6. Braak H, Braak E, Yilmazer D et al. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 1996; 103: 455-490
7. Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
8. Jellinger KA. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999; 56: 1-29
9. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265-1268
10. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533-535
11. Klawans HL. Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm Suppl 1988; 27: 117-122
12. Aarsland D, Larsen JP, Lim NG et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-496
13. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26: 643-659
14. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710-714
15. Diener HC, Hacke W. Leitlinien für Diagnostik und Therapie und der Neurologie. Stuttgart: Thieme, 2002
16. Group PS. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999; 340: 757-763
17. Group FCS. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999; 353: 2041-2042
18. Fernandez HH, Trieschmann ME, Burke MA et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18: 510-514
19. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14: 484-487
20. Dewey RB jr, O'Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000; 55: 1753-1754
21. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17: 676-681
22. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000; 20: 54-60
23. Juncos JL, Roberts VJ, Evatt ML et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19: 29-35
24. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998; 10: 216-219
25. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513-515
26. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 579-581
27. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord 2002; 17: 221-222
28. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52: 782-785
29. Miller CH, Mohr F, Umbricht D et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59: 69-75
30. Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-563
31. 3 receptor antagonist. Neurology 1995; 45: 1305-1308
32. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47: 1608-1609
33. Grace J, Daniel S, Stevens T et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13: 199-205
34. Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr 2001; 13: 277-288
35. McKeith I, Ser T del, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036
36. Hutchinson M, Fazzini E. Cholinesterase inhibitor in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 1319-1325
37. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-1174
38. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-712